(Alliance News) - Fusion Antibodies PLC on Tuesday said it has filed a patent application for a panel of antibodies that bind to an important target for cancer therapeutics.
Fusion Antibodies is a contract research organisation providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market. It is based in Belfast.
Fusion said the antibodies have the potential to inhibit the pro-tumourigenic activity of their target in cancer, which is supported by pre-clinical data.
It added that it exploring options to out-licence these antibodies to a clinical development company to progress them into Phase I clinical trials.
Chief Executive Officer Adrian Kinkaid said: "We have a dedicated team of scientists who continue to work on antibody discovery and expression, and we remain confident in our ability to grow and create opportunities in this field. We look forward to being able to update the market further, whilst also growing our patent portfolio."
Shares in Fusion were down 2.9% to 33.00 pence each in London on Tuesday morning.
By Sophie Rose, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Fusion Antibody (FAB)